Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Francesca Zammarchi, Karin Havenith, Simon Chivers, Paul W. Hogg, Charlie Britten, Sandamali Dissanayake, Peter Tyrer, Francois Bertelli, Ian Hutchinson, Luke Masterson, Phil Howard, John A. Hartley and Patrick H. van Berkel | ||||||||||||
Title | Abstract 2792A: Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/78/13_Supplement/2792A | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADCT-601 | ADCT601|ADCT 601|BGB 601|BGB601|BGB-601 | AXL Antibody 5 | ADCT-601 (BGB 601) is an antibody-drug conjugate (ADC) comprising an antibody targeting AXL linked to PL1601, which delivers the cytotoxic agent SG3199 to AXL-expressing tumor cells, potentially leading to decreased tumor growth (Cancer Res July 1 2018 (78) (13 Supplement) 2792A). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|